ZYDUSLIFE

Zydus Lifesciences Limited
Large-capPharma ↗

What the six lenses say about ZYDUSLIFE — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1159.0
2026-07-10
VWAP · 1Y anchor
₹989
+17.2% from VWAP
P/E · TTM
23.1×
TTM EPS ₹50.1
52-week range
100%
position low→high
RSI(14)
70
momentum

Own sector index

Pharma ↗
Overweight

1M

+6.2%

3M

+15.8%

1Y

+16.2%

Breadth >EMA21

72%

How ZYDUSLIFE’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
10.0
avg conviction decile
Leadership
1/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Large-cap cohortDRaw
TechnicalD10100›

The actual numbers

Price vs VWAP (1y)+17.2%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+18.0%
Price vs 50-EMA+9.0%
RSI(14)70
RS vs Nifty 500 · 3M+23.3%
RS vs sector · 3M+10.9%
52-week range100%
Volume vs 30d avg0.56×
Volume vs 60d avg0.51×
ATR(14) · volatility27.6
Bollinger width · vol contraction0.101
FundamentalD1081›

The actual numbers

Return on equity (ROE)21.2%
Return on capital (ROCE)21.2%
Operating margin26.0%
Net margin18.9%
Revenue growth · YoY+16.8%
EPS growth · YoY+11.4%
Debt / equity0.46×

Full 8-quarter history in the financials table below.

ValuationD634›

The actual numbers

P/E (TTM)23.1×
TTM EPS₹50.1
52-week range100%
CatalystD1094›

The actual numbers

Earnings & momentum160
Capital actions79
Governance154

Every filing in the corporate-announcements panel below.

FlowD1060›

The actual numbers

Promoter holding75.0%
Delivery · 30d avg51.8%
Up/down-day asymmetry-0.2pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Large-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D10 ) ÷ 2 = 10.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
96
Conviction score 96/100 · avg-decile strength 10.0/10

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.6pp
+6.3pp
+2.3pp
+27.0pp
+36.2pp
+24.6pp
Nifty 500
Broad-market baseline
+0.2pp
+6.2pp
+1.7pp
+23.3pp
+31.2pp
+20.8pp
Sector
Own-sector index
—
—
-0.7pp
+10.9pp
+16.8pp
+2.9pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

ZYDUSLIFE daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1159.00+11.00

Relative strength

RS vs baseline · rebased to 100

ZYDUSLIFE ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
97.77+0.20

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)6,2085,2375,2696,5286,5746,1236,8647,587
↳ change QoQ—-15.6%+0.6%+23.9%+0.7%-6.9%+12.1%+10.5%
EBITDA (₹cr)2,1471,5301,4452,1262,0882,0161,8162,554
EBITDA margin34.6%29.2%27.4%32.6%31.8%32.9%26.5%33.7%
PAT (₹cr)1,4839201,0261,2441,5211,2391,0231,341
↳ change QoQ—-37.9%+11.5%+21.2%+22.3%-18.5%-17.4%+31.1%
Net margin23.9%17.6%19.5%19.1%23.1%20.2%14.9%17.7%
EPS (₹)14.119.0610.1711.6414.5812.5110.3612.65
D/E————————
YoY growth · Mar '26Revenue +16.2% YoYPAT +7.8% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

…and 5 more.

Ownership

Who holds ZYDUSLIFE

Mutual funds holding ZYDUSLIFE (10)

FundWeightAUM ₹crGrade
Parag Parikh Flexi Cap Reg Gr1.49%1,43,388
Kotak Flexicap Reg Gr2.07%55,850
Parag Parikh ELSS Tax Saver Reg Gr1.62%5,600
LIC MF Large & Mid Cap Reg Gr1.08%2,983
Sundaram Multi Cap Gr1.06%2,807
HDFC Pharma and Healthcare Reg Gr2.50%2,362
Mahindra Manulife Flexi Cap Reg Gr1.02%1,527
Edelweiss Large Cap Gr0.59%1,422
Edelweiss Large Cap B Gr0.59%1,422
Edelweiss Large Cap C Gr0.59%1,422

ETFs holding ZYDUSLIFE (10)

ETFWeightGrade
Nippon India Nifty Pharma ETF3.01%
DSP Nifty Healthcare ETF2.60%
Aditya BSL Nifty Healthcare ETF2.60%
Axis NIFTY Healthcare ETF2.60%
ICICI Pru Nifty Healthcare ETF2.56%
Mirae Asset Nifty 500 Healthcare ETF2.14%
Motilal Oswal BSE Healthcare ETF1.84%
ICICI Pru Nifty Next 50 ETF1.14%
UTI Nifty Next 50 ETF1.14%
F00000VIPU1.14%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma